Implantica publishes Interim Report Q4, January-December 2020
“The extraordinary 3-year results of our pivotal RefluxStop™ clinical trial was the highlight of the fourth quarter, with patient data supporting that RefluxStop™ has the attributes to cause a paradigm shift in acid reflux treatment.”- Peter Forsell, CEO and Founder of ImplanticaSignificant events during the fourth quarter, 2020 · Implantica’s RefluxStop™ trial showed exceptional three-year follow-up results. None of the patients in the study were in need of regular daily use of PPIs (proton-pump inhibitors), which were taken by all before surgery. · Implantica completed a pre-